Management transactions

Each manager must notify Optomed and the FIN-FSA of every transaction in the financial instruments of the company conducted on his/her own account.¹

Last modified: 30.11.2022

The notifications shall be made promptly and no later than three business days after the date of the transaction (T+3).

In light of Optomed’s obligation to publish such information, managers must submit an informal notice to Optomed (sakari.knuutti@optomed.com and susanna.latvala-andersson@optomed.com) on the date of the transaction and that the actual notification is made to Optomed at the latest within two business days after the date of the transaction (T+2).

The notification shall be sent in electronic format to Optomed’s insider administration (sakari.knuutti@optomed.com and susanna.latvala-andersson@optomed.com) and to the FIN-FSA (by sending a secure email at the web page https://securemail.bof.fi to the address johdonkaupat@finanssivalvonta.fi) by using the form approved by the FIN-FSA, which is available at the FIN-FSA’s website (Related Document G) and include the information specified therein. The company’s insider administration may be contacted for further information.

If a manager authorises another person (e.g. an asset manager) to make the notifications on its behalf, information thereof (and the contact details of the relevant authorised persons) shall be submitted to the insider administration in writing. Such authorisation does not relieve the relevant manager from his/her liability.

1 Under MAR, a person’s obligation to notify transactions applies in respect of the relevant person, once a total amount of EUR 5,000 has been reached within a calendar year (the threshold is calculated by adding without netting all transactions conducted within a certain calendar year).However, Optomed recommends that all transactions are notified (also below the threshold). Optomed also intends to publish all transactions notified to Optomed (whether or not the 5,000 euro limit has been reached).

 

Management holdings:

Optomed discloses manager’s transactions as stock exchange releases no later than three business days after the date of the transaction (T+3). The contents of this site are updated at least quarterly.

Board and Management shareholding 30 November 2022:

  Name

Position

 

Own and
controlled shares

Options

 

  Petri Salonen

Chairman of the Board of Directors

9,367

  Mars Duan

Member of the Board of Directors

0

  Seppo Mäkinen

Member of the Board of Directors

8,787

  Anna Tenstam

Member of the Board of Directors

3,787

  Reijo Tauriainen

Member of the Board of Directors

11,886

  Total

33,827

 

  Name

Position

 

Own and
controlled shares

Options

 

  Seppo Kopsala

CEO

202,712

60,000¹

  Sakari Knuutti

Chief Financial Officer

0

40,0003

  Markku Myllylä

Vice President, Software

0

180,0005

  Laura Piila

Vice President, Devices

2000

68,0006

  Total

204,712

488,000

 

¹) Of which 40,000 under the 2015 option program and 20,000 under the 2017 option program.
²) Of which 8,000 under the 2018C option program, 26,000 under the 2019D option program and 6,000 under option program 2020A.
3) Of which 20,000 under the 2019C option program, 14,000 under the 2019D option program and 6,000 under option program 2020A.
4) Of which 100,000 under the 2019B option program.
5) Of which 60,000 under the 2018C option program, 60,000 under the 2019A option program and 60,000 under option program 2020A..
6) Of which 18,000 under the 2015 option program, 10,000 under the 2017 option program, 20,000 options under the 2017B option program and 20,000 under the 2019D option program.